-
BPC-157 vs TB-500: What Each One Actually Does
You probably heard about BPC-157 and TB-500 the same way most people did. A podcast — Joe Rogan, Huberman Lab, the Diary of a CEO episode with Dr. Alex Tatem. Or because the FDA pulled both compounds off the compounding pharmacy list in 2023. Or because someone at your gym mentioned the “Wolverine stack.” They…
-
Diary of a CEO Peptides: Every Compound Dr. Tatem Discussed
Plain-English breakdown of every peptide Dr. Alex Tatem named on Diary of a CEO – BPC-157, TB-500, Epitalon, and more. Research use only.
-
Semaglutide vs Tirzepatide vs Retatrutide: What the Research Actually Shows
A mechanistic and trial-data comparison of semaglutide (GLP-1R), tirzepatide (GLP-1R/GIPR), and retatrutide (GLP-1R/GIPR/GCGR) — covering STEP, SURMOUNT, SURPASS-2, and Phase 2 retatrutide data.
-
CJC-1295 + Ipamorelin: Why Research Protocols Stack Them
CJC-1295 (no DAC) activates GHRH receptors on pituitary somatotrophs; Ipamorelin suppresses somatostatin via GHS-R1a. Together they drive a discrete, amplified GH pulse that neither compound produces alone.
-
TB-500: Actin Regulation, Tissue Repair, and the Research Evidence
TB-500 is a synthetic 17-amino-acid fragment of thymosin beta-4, studied for its role in actin sequestration, angiogenesis, and tissue repair. A research-focused review of the mechanism, animal model evidence, and human data.
-
BPC-157: Mechanism, Evidence, and What the Literature Actually Says
BPC-157 mechanism reviewed: VEGF, eNOS, and GH receptor pathways, animal model evidence, honest human data gaps, dosing in research literature, and safety profile.
-
Welcome to the Peptigo Research Archive
Mechanism deep-dives, reconstitution protocols, and literature reviews on the peptides in our catalog. Written by our lab team, reviewed by the researchers we work with.